Section Arrow
TRVI.NASDAQ
- Trevi Therapeutics
Quotes are at least 15-min delayed:2026/07/17 10:02 EDT
Regular Hours
Last
 19.055
+1.695 (+9.76%)
Day High 
19.29 
Prev. Close
17.36 
1-M High
20.15 
Volume 
1.50M 
Bid
19.01
Ask
19.1
Day Low
17.23 
Open
17.585 
1-M Low
15.41 
Market Cap 
2.46B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 18.01 
20-SMA 17.87 
50-SMA 15.63 
52-W High 20.15 
52-W Low 6.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.32/-0.41
Enterprise Value
2.47B
Balance Sheet
Book Value Per Share
1.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ATAIAtaiBeckley Inc7.135-0.015-0.21%-- 
OTLKOutlook Therapeutics1.3999-0.0601-4.12%-- 
LIMNLiminatus Pharma Inc0.1216-0.0261-17.67%-- 
IOVAIovance Biotherapeutics4.825+0.165+3.54%-- 
RGNXREGENXBIO9.12-2.08-18.57%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.